| Ytd | -52.81% | |
| 1y | -91.62% |
| Open | 4.50 | Prev Close | 4.44 | Low | 4.16 | High | 4.50 | Mkt Cap | 5.55M |
| Vol | 21.18K | Avg Vol | 33.26K | EPS | 1488.13 | P/E | 0.00 | Forward P/E | -0.83 |
| Beta | 5.07 | Short Ratio | 0.47 | Inst. Own | 11.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.83 | 200-d Avg | 12.94 | 1yr Est | 21.00 |
SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-s
https://patentcenter.uspto.gov/applications/16871597/ifw/docshttps://x.com/PatentGrants/status/20597
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel mult
The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the anal
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy al
Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immu